Dexmedetomidine and acute kidney injury in patients with sepsis: a retrospective cohort study
5
item.page.dc.date.issued
2025-01-01
item.page.dc.type
item.page.dc.identifier.issn
0832610X
item.page.dc.identifier.eissn
14968975
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-105007675113
item.page.oaire.citation.title
Canadian Journal of Anesthesia
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Canadian Journal of Anesthesia (2025)
punsarn.item.page.citation
Chaengsuthiworawat P., Thampongsa T., Thamjamrassri T., Pisitsak C. Dexmedetomidine and acute kidney injury in patients with sepsis: a retrospective cohort study. Canadian Journal of Anesthesia (2025). doi:10.1007/s12630-025-02977-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110780
item.page.dc.title
Dexmedetomidine and acute kidney injury in patients with sepsis: a retrospective cohort study
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
Purpose: Acute kidney injury (AKI) is a common complication of sepsis. AKI is associated with increased morbidity and mortality. Studies show that dexmedetomidine has a protective effect against AKI. We sought to evaluate the association between dexmedetomidine administration and AKI in patients with sepsis. Methods: We conducted a retrospective cohort study of 331 adult patients with sepsis. We divided patients into two groups: patients who received an infusion of dexmedetomidine of ≥ 0.2 µg·kg<sup>−1</sup>·hr<sup>−1</sup> for > 6 hr within 72 hr of sepsis diagnosis (the dexmedetomidine group; N = 73) and patients who did not receive a dexmedetomidine infusion (the nondexmedetomidine group; N = 258). The primary outcome was the incidence of AKI within seven days, defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria. We analyzed our results using multivariable logistic regression models including 1) the entire cohort (331 patients) or 2) a 1:1 propensity-score-matched cohort (73 patients per group). Results: Acute kidney injury was diagnosed in 190/331 (57.4%) patients. The incidence of AKI was not different between the dexmedetomidine group and the nondexmedetomidine group in both the entire cohort (54.8% vs 58.1%; P = 0.61) and the propensity-matched cohort (54.7% vs 63.0%; P = 0.31). Additionally, there were no significant differences between groups in the incidence of renal replacement therapy (10.9% vs 13.6%; P = 0.61) and 30-day mortality (32.8% vs 24.6%; P = 0.27). We observed a statistically significant interaction between patient age > 65 yr and reduced odds of developing AKI in patients who received dexmedetomidine (adjusted odds ratio, 0.25; 95% confidence interval, 0.07 to 0.90; P = 0.03). Conclusions: While there was no association between dexmedetomidine administration and AKI in our overall cohort of patients with sepsis, we observed reduced odds of developing AKI in older patients (aged > 65 yr) who received dexmedetomidine. Further research is needed to confirm that dexmedetomidine has a protective effect against AKI in this patient population.